3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Sarcoma
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Metastatic Solid Tumors
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
44
Gemcitabine
23
Nivolumab
21
enfortumab vedotin
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
16
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
bintrafusp alfa protein, human
×
1 year
×
Clear all
No trials found.